The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index; none of the 32 sources its claims cite is checked for support yet.
Bacteroides vulgatus and Bacteroides dorei Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Atherosclerosis
Abstract
Background: It is increasingly recognized that gut microbiota play a pivotal role in the development of atherosclerotic cardiovascular disease. Previously, we have reported that the abundance of genus Bacteroides is lower in patients with coronary artery disease (CAD) than in patients without CAD with coronary risk factors or in healthy volunteers. However, it remains unclear which and how specific gut bacteria contribute to the progression of atherosclerosis. Methods: We recruited patients with CAD patients and controls without CAD with coronary risk factors. We then compared gut microbial composition using 16S ribosomal RNA gene sequencing in fecal samples to detect species with differential abundance between 2 groups. Subsequently, we used atherosclerosis-prone mice to study the mechanisms underlying the relationship between such species and atherosclerosis. Results: Human fecal 16S ribosomal RNA gene sequencing revealed a significantly lower abundance of Bacteroides vulgatus and Bacteroides dorei in patients with CAD. This significant differential abundance was confirmed by quantitative polymerase chain reaction. Gavage with live B. vulgatus and B. dorei attenuated atherosclerotic lesion formation in atherosclerosis-prone mice, markedly ameliorating endotoxemia followed by decreasing gut microbial lipopolysaccharide production, effectively suppressing proinflammatory immune responses. Furthermore, fecal lipopolysaccharide levels in patients with CAD were significantly higher and negatively correlated with the abundance of B. vulgatus and B. dorei . Conclusions: Our translational research findings identify a previously unknown link between specific gut bacteria and atherosclerosis. Treatment with live B. vulgatus and B. dorei may help prevent CAD. Clinical Trial Registration: URL: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018051 . Unique identifier: UMIN000015703.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In patients with coronary artery disease (CAD), gut abundance of *Bacteroides vulgatus* and *Bacteroides dorei* was lower than in controls without CAD, and fecal lipopolysaccharide (LPS) levels were higher. In atherosclerosis-prone mice, oral gavage with live *B. vulgatus* and *B. dorei* reduced fecal and plasma LPS, dampened inflammation, and attenuated atherosclerotic plaque.
Key findings
- In 30 patients with CAD versus 30 age- and sex-matched controls without CAD but with coronary risk factors, 16S rRNA sequencing showed relative depletion of *B. vulgatus* and *B. dorei* in CAD; qPCR confirmed significantly decreased abundance of these species.
- Fecal LPS levels were significantly higher in patients with CAD than controls, and fecal LPS correlated negatively with *B. vulgatus*/*B. dorei* abundance in CAD (r=−0.541, P=0.002); genus *Bacteroides* showed a trend toward negative correlation (r=−0.227, P=0.0838).
- In apolipoprotein E-deficient mice, gavage with live *B. vulgatus* and *B. dorei* (2.5×10⁹ cfu/100 μL, 5 times/week) significantly reduced aortic root and en face atherosclerotic lesion size, macrophage and CD4⁺ T-cell accumulation, plasma LPS, and proatherogenic cytokines, without significant differences in body weight, plasma cholesterol, or plasma glucose.
- Live *Bacteroides* treatment decreased predicted microbial LPS biosynthesis genes *LpxA* and *LpxD* and dramatically lowered fecal LPS; heat-killed *Bacteroides* did not decrease fecal LPS, aortic sinus plaque, or plasma LPS compared with controls (reported P=0.92, P=0.74, and P=0.93, respectively).
Methods
- Human study: 30 patients with CAD and 30 controls without CAD with coronary risk factors were recruited at Kobe University Hospital between October 2014 and July 2015; fecal samples underwent 16S rRNA gene sequencing (V3–V4 region), qPCR, PICRUSt functional prediction, and limulus amebocyte lysate assay for LPS.
- Mouse study: 6-week-old female apolipoprotein E-deficient mice on C57BL/6 background were randomized to control, live *Bacteroides*, or heat-killed *Bacteroides* groups; mice were gavaged 5 times per week for 10 weeks and euthanized at 16 weeks for atherosclerosis, immune, gut permeability, and LPS analyses.
- Statistical analysis used R, JMP, and Prism; Shapiro-Wilk test, Student’s t test or Mann-Whitney U test, Fisher exact or χ² test, Spearman correlation, one-way ANOVA, and Benjamini-Hochberg adjustment for multiple comparisons.
Limitations
- The paper states that 16S rRNA sequencing has low phylogenetic power at the species level and poor discriminatory power for some genera, and that the human CAD gut microbial analysis was a single-center study with a relatively small number of patients.
- The paper states that controls without CAD did not all undergo coronary angiography, so subclinical CAD may have been present; the limulus amebocyte lysate assay could not measure LPS immunogenicity or the impact of *Bacteroides* on LPS structure/function; mechanisms of atherosclerosis protection by lower LPS were not completely elucidated; mouse and human dominant microbiota differ; and only *B. vulgatus* and *B. dorei* were tested, so more effective strains may exist.
- Evident from the text: the human findings are cross-sectional and cannot establish causality, and the causal evidence comes from a mouse gavage model rather than a human intervention.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 32 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“immunohistochemical staining followed by morphometric analysis of atherosclerotic lesions in the aortic sinus revealed a marked reduction in macrophage and CD4 + T-cell accumulation in mice gavaged with live Bacteroides compared with controls (Figure 2C and 2D).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we observed significantly higher expression levels of ZO-1 (mRNA and protein) in HT29 cells stimulated with fecal supernatant from live Bacteroides-treated mice than in cells stimulated with fecal supernatant from control mice (Figure VD and VE in the online-only Data Supplement).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Live Bacteroides Treatment Strengthened Tight Junction Formation In Vivo and In Vitro
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we found that the abundance of Bacteroides vulgatus and Bacteroides dorei was decreased in patients with CAD.”
- Also stated in: § Gut Microbial Profile in Patients With CAD · plain
“patients with CAD showed a relative depletion of B. vulgatus and B. dorei”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Gut Microbial Profile in Patients With CAD · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mRNA expression of several proatherogenic immune cell markers and chemokines/ chemokine receptors was decreased in mice gavaged with live Bacteroides (Figure 2E).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“reflected in higher mean fluorescence intensity of ZO-1 in the colon (Figure VC in the online-only Data Supplement).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Live Bacteroides Treatment Strengthened Tight Junction Formation In Vivo and In Vitro
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although the expression of genes related to TMA synthesis (CutC, CutD) had no difference among the groups”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gavage With Live Bacteroides Alters Gut Microbial LPS Production
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found that the relative abundance of the genus Bacteroides was visibly lower in patients with CAD compared with controls (Figure 1G).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The abundance of B. vulgatus and B. dorei was considerably higher in feces from live Bacteroides-gavaged mice (Figure IIIF in the online-only Data Supplement).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gavage With Live Bacteroides Alters Gut Microbial LPS Production
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“the expression of genes involved in LPS biosynthesis, especially LpxA and LpxD, which are involved in lipid A biosynthesis and constitute the essential acyltransferases of the lipid A structure (Figure 3B), 38,39 was significantly decreased in mice gavaged with live Bacteroides (Figure 3A and 3C, Figure IV in the online-only Data Supplement).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gavage With Live Bacteroides Alters Gut Microbial LPS Production
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We also confirmed the significantly decreased abundance of B. vulgatus and B. dorei in patients with CAD by quantitative polymerase chain reaction (Figure 1J and Table II in the online-only Data Supplement).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 29
- Probably not a substantial claim. 21
- The quote only partly states this claim. 2
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“mice gavaged with Bacteroides exhibited decreased expression of major histocompatibility complex class II and costimulatory molecule CD86, as well as increased expression of the coinhibitory molecules programmed death ligand-1 and programmed death ligand-2 on splenic CD11c high dendritic cells (Figure IIB in the online-only Data Supplement).”
- Also stated in: § ORIGINAL RESEARCH ARTICLE · plain
“Similar phenotypic changes along with increased expression of PD-L1 and PD-L2 in dendritic cells were observed in the spleen.”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § ORIGINAL RESEARCH ARTICLE · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the samples were clustered into 3 clusters at the genus level”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Strength:plain· not yet calibratedn = 30Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“mice gavaged with live Bacteroides showed significantly reduced lesion size in the aortic root and en face analysis of thoracoabdominal aortas (Figure 2A and 2B)”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The controls without CAD were significantly more likely to be categorized into cluster 1, whereas few patients with CAD were categorized into this cluster (Figure 1F).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“without significant difference in body weight (Figure 2F), plasma cholesterol levels (Figure 2G), or plasma glucose levels (data not shown).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Each cluster was characterized by a high abundance of a specific genus as follows: Bacteroides in cluster 1, Prevotella in cluster 2, and Faecalibacterium, Ruminococcus, or Bifidobacterium in cluster 3 (Figure 1E).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Mice gavaged with live Bacteroides had lower numbers of effector CD44 high CD62Llow CD4 + T cells and a significantly higher proportion of CD4 + CD25 + Foxp3 + regulatory T cells, with higher levels of intracellular CTLA4 (Figure IID and IIE in the online-only Data Supplement)”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“patients with CAD showed a relative depletion of B. vulgatus and B. dorei and enrichment in Faecalibacterium prausnitzii and Prevotella copri (Figure 1H).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The α diversity, Bacteroidetes/Firmicutes ratio, and Gram-positive to Gramnegative strain ratio did not differ significantly between the 2 groups (Figure 1A and 1C).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Strength:plain· not yet calibratedn = 30Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“were the 2 most abundant species within the genus Bacteroides in 16S rRNA gene sequencing analysis (Figure 1I).”
- Also stated in: § DISCUSSION · plain
“B. vulgatus and B. dorei are the dominant species of genus Bacteroides in human gut microbiota.”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one. The quote only partly states this claim.
- Also stated in: § DISCUSSION · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Bacteroidetes/Firmicutes ratio, Gram-positive to Gram-negative strain ratio, and fecal water content did not differ significantly among the 3 groups”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Affiliations
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“whereas the number of CD4 + T cells and several markers on CD4 + T cells did not significantly change (Figure VIC and VIF in the online-only Data Supplement).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we found that fecal LPS levels were higher in patients with lower abundance of B. vulgatus and B. dorei.”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe quote only partly states this claim.
- Rests on an assumption: Fecal lipopolysaccharide levels reflect colon lipopolysaccharide concentrations produced by gut microbiota.
None of the sources cited for this claim have been checked yet.
In the paper
“Trimethylamine (TMA) and TMA N-oxide, which are gut microbiota metabolites of dietary phosphatidylcholine, are known to be associated with cardiovascular disease and with the atherosclerosis process in particular.3,4”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Abstract
Strength:boosted· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“CAD remains the leading cause of morbidity and mortality worldwide, despite the widespread use of statin therapy in the last decade.12”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Abstract
What the sources say
- Not checked yetcites [12] source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Endotoxemia is known to cause systemic inflammation leading to the disruption of innate and adaptive immunity and the development of atherosclerosis.[34][35][36]”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
What the sources say
- Not checked yetcites [34]
- Not checked yetcites [35] source
- Not checked yetcites [36]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“a recent clinical trial has shown contradictory results indicating that fish consumption drastically increases circulating TMA N-oxide levels”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Abstract
What the sources say
- Not checked yetcites [6] source
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“This study was approved by the Ethics Committee of Kobe University (approval No. 1595) and registered with the University hospital Medical Information Network Clinical Trials Registry (trial registration No. UMIN000015703).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Recruitment of Patients With CAD and Controls
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The success of the heat treatment was confirmed by the absence of growth of plated heat-killed bacteria.”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Animals
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All participants provided written informed consent on enrollment, and the study was conducted according to the guidelines of the Declaration of Helsinki.”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Recruitment of Patients With CAD and Controls
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All experiments were performed according to the Guidelines for Animal Experiments in effect at Kobe University School of Medicine (guideline No. P160701).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Animals
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“However, it remains unclear which specific Bacteroides species are involved and what their exact role is in CAD.11”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Abstract
What the sources say
- Not checked yetcites [11]
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Six-week-old mice were randomly divided into 3 treatment groups”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Animals
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“Because these 2 species share similar 16S rRNA sequencing patterns, 32 we were not able to distinguish them using our methodology.”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
What the sources say
- Not checked yetcites [32]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The sample size was calculated using R software (power=0.9,significance level=0.05,mean difference=6, SD=7; n=30 per group.).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Recruitment of Patients With CAD and Controls
Strength:plain· not yet calibratedn = 30Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The genus Bacteroides includes some of the predominant gut bacteria in humans and is known to have an important role in maintaining a healthy gut ecosystem.7”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Abstract
What the sources say
- Not checked yetcites [7]
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Because LPS stimulates cells through TLR4 and upregulates costimulatory molecules on antigen-presenting cells, 37”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
What the sources say
- Not checked yetcites [37]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These results suggested that replenishment of live B. vulgatus and B. dorei by oral gavage reduced plaque inflammation, attenuating atherosclerotic lesion formation.”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The effects of live B. vulgatus and B. dorei on atherosclerosis in apolipoprotein E-deficient mice are representative of human coronary artery disease.
None of the sources cited for this claim have been checked yet.
In the paper
“Although LPS from E. coli increases intestinal permeability in a TLR4-dependent manner, 40,41”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
What the sources say
- Not checked yetcites [40]
- Not checked yetcites [41]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“because we did not perform coronary angiography for all the controls without CAD, there might have been individuals with subclinical CAD in the control group”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“These limitations imply that we did not fully elucidate the characteristics of gut microbial composition in CAD”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“16S rRNA sequencing analysis helped to seek candidate and translate to animal experiments”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“Given that gut microbiota-derived LPS and systemic endotoxemia are involved in the onset and progression of not only atherosclerosis but also many prevalent disorders, such as inflammatory bowel disease, obesity and related metabolic diseases, and nonalcoholic steatohepatitis, [47][48][49]”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
What the sources say
- Not checked yetcites [47][48][49]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“the gut microbial analysis in patients with CAD was a single-center study with a relatively small number of patients”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“used a mouse model to clarify the causal relationship between B. vulgatus and B. dorei and atherosclerosis”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“the LPS compounds penta-and tetraacylated lipid A of these Bacteroides species are structur-ally distinct from the hexa-acylated LPS of E.scherichia coli and elicit reduced TLR4 responses.33”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > DISCUSSION
What the sources say
- Not checked yetcites [33] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These results strongly support the idea that B. vulgatus and B. dorei regulate gut microbial production of LPS and that their activity can influence the progression of atherosclerosis in patients with CAD.”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: Fecal lipopolysaccharide levels reflect colon lipopolysaccharide concentrations produced by gut microbiota.
- Rests on an assumption: The effects of live B. vulgatus and B. dorei on atherosclerosis in apolipoprotein E-deficient mice are representative of human coronary artery disease.
None of the sources cited for this claim have been checked yet.
In the paper
“we considered that augmentation of these tolerogenic dendritic cells' phenotype in MLNs or spleen was suspected to migrate into the blood and was closely associated with attenuated atherosclerotic lesion formation as previously reported.42,43,46”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
What the sources say
- Not checked yetcites [42]
- Not checked yetcites [43]
- Not checked yetcites [46]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- The authors state this as an assumption: Decreased circulating lipopolysaccharide levels after live Bacteroides treatment may reduce expression of TLR4, CCR7, CCL17, and CCL21 in the aorta, resulting in less macrophage and CD4+ T cell accumulation in atherosclerotic plaque.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“we performed gavage only with B. vulgatus and B. dorei”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we believe that B. vulgatus and B. dorei might improve the enteric environment, providing gut bacteria with good living conditions and having a beneficial effect on bacterial LPS production.”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“we did not completely elucidate the mechanisms of atherosclerosis protection by lower LPS concentrations in mice”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“it could not measure LPS immunogenicity and the impact of Bacteroides on the structure and function of LPS”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The authors state this as an assumption.
Decreased circulating lipopolysaccharide levels after live Bacteroides treatment may reduce expression of TLR4, CCR7, CCL17, and CCL21 in the aorta, resulting in less macrophage and CD4+ T cell accumulation in atherosclerotic plaque.
“it is intriguing to assume that decreased circulating LPS levels after live Bacteroides treatment may reduce the expression of TLR4, CCR7, CCL17, and CCL21 in the aorta, resulting in less macrophage and CD4 + T cell accumulation in atherosclerotic plaque.”
The paper relies on this without support.
Fecal lipopolysaccharide levels reflect colon lipopolysaccharide concentrations produced by gut microbiota.
“we measured fecal LPS levels as an indicator of colon LPS concentrations pro-duced by gut microbiota.”
The paper relies on this without support.
The effects of live B. vulgatus and B. dorei on atherosclerosis in apolipoprotein E-deficient mice are representative of human coronary artery disease.
“Bacteroides treatment may serve as a novel and attractive therapeutic strategy for suppressing lipopolysaccharide-induced inflammatory response in CAD.”
The paper relies on this without support.
The hospital diet consumed by participants did not confound the gut microbiome or fecal lipopolysaccharide measurements.
“Fecal samples were collected while participants were hospitalized and thus consuming a hospital diet for >1 day.”
The paper relies on this without support.
The impact of colon lipopolysaccharide concentrations on intestinal permeability has not been fully investigated to date.
“the impact of colon LPS concentrations on intestinal permeability has not been fully investigated to date.”
The paper relies on this without support.
A specific gut microbiota-based target to prevent coronary artery disease has yet to emerge.
“a specific gut microbiota-based target to prevent CAD has yet to emerge.”
The paper relies on this without support.
Gut microbial profiles depend on age, sex, local food or lifestyle, and many other factors, making it difficult to define dysbiosis in atherosclerosis.
“it is difficult to conclude the definition of dysbiosis in atherosclerosis because each gut microbial profile depends on age, sex, local food or lifestyle, and many other factors”
The paper relies on this without support.
16S rRNA sequencing analysis has low phylogenetic power at the species level and poor discriminatory power for some genera.
“It has low phylogenetic power at the species level and poor discriminatory power for some genera”
The paper relies on this without support.
The relative abundances of most of the dominant gut microbiota in mice and humans are quite different.
“the relative abundances of most of the dominant gut microbiota in mice and human are quite different”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, gavage with the gram-negative Bacteroides (vulgatus and dorei) that produce penta- and tetra-acylated lipid A – in contrast to the hexa-acylated lipid A of e. coli, reduced colonic inflammation, endotoxemia, and atherosclerosis in ApoE−/− mice31.”
From Gut microbiota and cardiovascular disease. (2020) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Two different articles are assigned the same DOI
MinorReferences 31 and 33 give the identical DOI for articles with different titles, journals, and page ranges. At least one DOI is incorrect.
“Variation in microbiome LPS immunogenicity contributes to autoim- munity in humans. Cell. 2016;165:842-853. doi: 10.1002/art.39783”
“Dysbio- sis contributes to arthritis development via activation of autoreactive T cells in the intestine. Arthritis Rheumatol. 2016;68:2646-2661. doi: 10.1002/art.39783”
Citations
Cites
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
Search and clustering orders of magnitude faster than BLAST
Edgar, R. C. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq461 · Cited by 21,098
Naive Bayesian Classifier for Rapid Assignment of rRNA Sequences into the New Bacterial Taxonomy
Wang, Q., Garrity, G. M., Tiedje, J. M., & Cole, J. R. (2007) · Applied and Environmental Microbiology · doi:10.1128/aem.00062-07 · Cited by 20,145
UPARSE: highly accurate OTU sequences from microbial amplicon reads
Edgar, R. C. (2013) · Nature Methods · doi:10.1038/nmeth.2604 · Cited by 16,770
UCHIME improves sensitivity and speed of chimera detection
Edgar, R. C., Haas, B. J., Clemente, J. C., Quince, C., & Knight, R. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr381 · Cited by 15,114
Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences
Langille, M. G. I., Zaneveld, J., Caporaso, J. G., McDonald, D., Knights, D., Reyes, J. A., Clemente, J. C., Burkepile, D. E., Vega Thurber, R. L., Knight, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2676 · Cited by 9,116
KEGG: new perspectives on genomes, pathways, diseases and drugs
Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y., & Morishima, K. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1092 · Cited by 8,865
Enterotypes of the human gut microbiome
MetaHIT Consortium (additional members), Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D. R., Fernandes, G. R., Tap, J., Bruls, T., et al. (2011) · Nature · doi:10.1038/nature09944 · Cited by 7,548
Self-citationRosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1002/art.39783 · DOI · Paper page
Cited by
Sorted by citations
Items 101–200 of 625
Therapeutic potential of natural products against atherosclerosis: Targeting on gut microbiota
Zhao, X., Oduro, P. K., Tong, W., Wang, Y., Gao, X., & Wang, Q. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105362 · Cited by 47
Debédat, J., Roy, T. L., Voland, L., Belda, E., Alili, R., Adriouch, S., Lassen, P. B., Kasahara, K., Hutchison, E. R., Genser, L., et al. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2050635 · Cited by 51
Gut Microbiome in Chronic Coronary Syndrome Patients
Sawicka, E., Bondarczuk, K., Bauer, W., Niemira, M., Szalkowska, A., Raczkowska, J., Kwaśniewski, M., Tarasiuk, E., Dubatówka, M., Łapińska, M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215074 · Cited by 46
“dorei attenuated the development of atherosclerosis in atherosclerosis-prone mice [48].”
BackgroundChen, S., Wang, J., Dong, N., Fang, Q., Zhang, Y. L., Chen, C., Cui, S. W., & Nie, S. (2023) · Food & Function · doi:10.1039/d2fo02555h · Cited by 45
Gut microbiota and cardiac arrhythmia
Fan, H., Liu, X., Ren, Z., Fei, X., Luo, J., Yang, X., Xue, Y., Zhang, F., & Liang, B. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1147687 · Cited by 48
“Akkermansia muciniphila attenuates atherosclerotic lesions by ameliorating metabolic endotoxemiainduced inflammation through restoration of the gut barrier in apolipoprotein E-deficient (ApoE(-/-)) mice (Yoshida et al., 2018).”
BackgroundGut microecology: Why our microbes could be key to our health
Lu, D., Huang, Y., Kong, Y., Tao, T., & Zhu, X. M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110784 · Cited by 48
Yuan, S., & Shen, J. (2020) · Bone · doi:10.1016/j.bone.2020.115710 · Cited by 40
Novel insights in the relationship of gut microbiota and coronary artery diseases
Ramírez-Macías, I., Orenes‐Piñero, E., Camelo-Castillo, A. J., Rivera‐Caravaca, J. M., López‐García, C., & Marín, F. R. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1868397 · Cited by 45
“These previous observations are in accordance with the results reported by Cui et al., where the phylum Bacteroidetes was the most representative phylum in CAD patients (56.12% in total) (Cui et al. 2017; Yoshida et al. 2018).”
BackgroundResultInfluentialZeng, Z., Xie, Z., Chen, G., Sun, Y., Zeng, X., & Liu, Z. (2021) · Food & Function · doi:10.1039/d1fo02702f · Cited by 43
Wu, R., Mei, X., Wang, J.-S., Sun, W., Xue, T., Lin, C., & Xu, D. (2019) · Food & Function · doi:10.1039/c9fo01034c · Cited by 43
Wang, S., Lv, Z., Zhao, W., Wang, L., & He, N. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.104194 · Cited by 45
Eubacterium rectale Attenuates HSV-1 Induced Systemic Inflammation in Mice by Inhibiting CD83
Islam, S. M. S., Ryu, H.-M., Sayeed, H. M., Byun, H., Jung, J., Kim, H., Suh, C., & Sohn, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.712312 · Cited by 43
“vulgatus attenuated atherosclerosis through Foxp3 upregulation and TNFa downregulation (63).”
BackgroundVan den Abbeele, P., Deyaert, S., Albers, R., Baudot, A., & Mercenier, A. (2023) · Nutrients · doi:10.3390/nu15092090 · Cited by 46
Periodontal bacteria influence systemic diseases through the gut microbiota
Xi, M., Ruan, Q., Zhong, S., Li, J., Qi, W., Xie, C., Wang, X., Abuduxiku, N., & Ni, J. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1478362 · Cited by 49
Yoshida, N., Sasaki, K., Sasaki, D., Yamashita, T., Fukuda, H., Hayashi, T., Tabata, T., Osawa, R., Hirata, K., & Kondo, A. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.47415 · Cited by 42
Self-citationGut microbiota dysbiosis in Chinese children with type 1 diabetes mellitus: An observational study
Liu, X., Cheng, Y., Shao, L., Sun, S., Wu, J., Song, Q., Hong-sheng, Z., & Ling, Z. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i19.2394 · Cited by 42
Bacterial lipopolysaccharide modulates immune response in the colorectal tumor microenvironment
Sulit, A. K., Daigneault, M. C., Allen‐Vercoe, E., Silander, O., Hock, B. D., McKenzie, J., Pearson, J. F., Frizelle, F., Schmeier, S., & Purcell, R. V. (2023) · npj Biofilms and Microbiomes · doi:10.1038/s41522-023-00429-w · Cited by 45
“Indeed, species of the Bacteroides genus, including B. fragilis , have been found to have immunoregulatory properties 40 – 42 .”
Martins, D., Silva, C., Ferreira, A. C., DOURADO, S. B., Albuquerque, A. C., Saraiva, F. A., Batista, A. B., Castro, P., Leite-Moreira, A. F., Barros, A. S., et al. (2024) · Biomolecules · doi:10.3390/biom14060731 · Cited by 45
Different Bacteroides Species Colonise Human and Chicken Intestinal Tract
Kollarcikova, M., Faldynová, M., Matiasovicova, J., Jahodářová, E., Kubasová, T., Seidlerová, Z., Babák, V., Videnska, P., Čížek, A., & Rychlı́k, I. (2020) · Microorganisms · doi:10.3390/microorganisms8101483 · Cited by 41
“ovatus were reported as common to human gut microbiota [8,9,25,26] and B.”
BackgroundSARS‐CoV‐2 triggered oxidative stress and abnormal energy metabolism in gut microbiota
Zhou, T., Wu, J., Zeng, Y., Li, J., Yan, J., Meng, W., Han, H., Feng, F., He, J., Zhao, S., et al. (2022) · MedComm · doi:10.1002/mco2.112 · Cited by 40
Ofosu, F. K., Elahi, F., Daliri, E. B., Aloo, S. O., Chelliah, R., Han, S., & Oh, D. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105666 · Cited by 39
Gut-microbiota prompt activation of natural killer cell on alcoholic liver disease
Eom, J. A., Jeong, J., Han, S. H., Kwon, G.-H., Lee, K. J., Gupta, H., Sharma, S. P., Won, S., Oh, K., Yoon, S. J., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2281014 · Cited by 39
“22,23 L. helveticus is known to modulate the host immune response and alleviate acute liver injury.”
BackgroundPermissive microbiome characterizes human subjects with a neurovascular disease cavernous angioma
Polster, S. P., Sharma, A., Tanes, C., Tang, A. T., Mericko, P. A., Cao, Y. J., Carrión‐Penagos, J., Girard, R., Koskimäki, J., Zhang, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16436-w · Cited by 41
Zhao, H., Luo, X., Shi, Y., Li, J., Pan, F., Ren, R., Peng, L., Shi, X.-Y., Yang, G., Wang, J., et al. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.554441 · Cited by 39
“22-μm filter successively and inactivated at 90C for 15min (28).”
BackgroundBakır-Güngör, B., Bulut, O., Jabeer, A., Nalbantoğlu, Ö. U., & Yousef, M. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.628426 · Cited by 41
“In another study, using a mouse model, Yoshida et al. (2018) found that B. vulgatus and B. dorei upregulates the expression of tight junction genes in the colon, which leads to reduction in gut permeability, reduction of lipopolysaccharides production, and amelioration of endotoxemia.”
Li, Y., Yu, Z., Liu, Y., Wang, T., Liu, Y., Bai, Z., Yi, R., Ma, H., Bao, T., Lu, H., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.830781 · Cited by 38
“Gut Microbiota Analysis The fecal microbial 16S rRNA gene sequencing and analysis were investigated as the previous studies (29).”
MethodThe gut microbiome across the cardiovascular risk spectrum
Prins, F. M., Collij, V., Groot, H. E., Björk, J. R., Swarte, J. C., Andreu‐Sánchez, S., Jansen, B. H., Fu, J., Harmsen, H. J. M., Zhernakova, A., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad377 · Cited by 40
Direct Action of Non-Digestible Oligosaccharides against a Leaky Gut
Mavrogeni, M. E., Asadpoor, M., Henricks, P. A. J., Keshavarzian, A., Folkerts, G., & Braber, S. (2022) · Nutrients · doi:10.3390/nu14214699 · Cited by 37
Gao, G., Cao, J., Mi, L., Feng, D., Deng, Q., Sun, X.-B., Zhang, H., Wang, Q., & Wang, J. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.07.172 · Cited by 35
Gut Dysbiosis in Pancreatic Diseases: A Causative Factor and a Novel Therapeutic Target
Zhang, T., Gao, G., Sakandar, H. A., Kwok, L., & Sun, Z. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.814269 · Cited by 39
Kang, J. T. L., Teo, J. J. Y., Bertrand, D., Ng, A. H. Q., Ravikrishnan, A., Yong, M., Ng, O. T., Marimuthu, K., Chen, S. L., Chng, K. R., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01221-w · Cited by 35
Haran, J. P., Zeamer, A. L., Ward, D. V., Dutta, P., Bucci, V., & McCormick, B. A. (2021) · The Journals of Gerontology Series A · doi:10.1093/gerona/glab167 · Cited by 36
Vitamin D, Gut Microbiota, and Cardiometabolic Diseases—A Possible Three-Way Axis
Sukik, A., Alalwani, J., & Ganji, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24020940 · Cited by 34
“In humans, a primary effect of dysbiosis is the translocation of bacterial metabolites such as LPS, which induces chronic low-grade inflammation through the production of pro-inflammatory cytokines such as IL-1β [65,66].”
BackgroundLiu, H., Wang, H., Li, Q., Wang, Y., He, Y., Li, X., Sun, C., Ergönül, Ö., Can, F., Pang, Z., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.06.005 · Cited by 34
Bacteroides and NAFLD: pathophysiology and therapy
Zhang, J., Zhou, J., He, Z., & Li, H. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1288856 · Cited by 37
Si, Z.-L., Wang, H., Wang, T., Cao, Y., Li, Q.-Z., Liu, K., Huang, Z., Liu, H., Tan, Y., Wang, Y.-Y., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114830 · Cited by 36
Mohr, A. E., Mach, N., Pugh, J. N., Grosicki, G. J., Allen, J. M., Karl, J. P., & Whisner, C. M. (2025) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuaf037 · Cited by 37
“Bacteroides vulgatus gavage in mice decreases gut microbial lipopolysaccharide (LPS) production, suppressing proinflammatory immune responses (Yoshida et al. 2018 ) and attenuating symptoms of dextran sodium sulfate-induced colitis (Liu et al. 2022a ).”
Mutual Interplay of Host Immune System and Gut Microbiota in the Immunopathology of Atherosclerosis
Yeh, C., Chen, Y.-H., Liu, S.-F., Kao, H., Wu, M., Yang, K., & Wu, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228729 · Cited by 37
Gut Microbiota and Environment in Coronary Artery Disease
Piccioni, A., de Cunzo, T., Valletta, F., Covino, M., Rinninella, E., Raoul, P. C., Zanza, C., Mele, M. C., & Franceschi, F. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18084242 · Cited by 34
“[30] Comparative 2018 30 CAD patients and 30 healthy controls CAD patients have a reduction of Bacteroides vulgatus and Bacteroides dorei.”
BackgroundMethodMa, Y., & Liu, Q. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105503 · Cited by 34
Sun, X., Chen, Z., Yu, L., Zeng, W., Sun, B., Fan, H., & Bai, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1205323 · Cited by 33
“, 2021), mitigate atherosclerosis, and suppress proinflammatory cytokine production (Yoshida et al., 2018).”
BackgroundZhu, X., Du, L., Zhang, L., Ding, L., Xu, W., & Lin, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1333086 · Cited by 33
Lupu, V. V., Trandafir, L. M., Răileanu, A. A., Mihai, C. M., Morariu, I. D., Stârcea, I. M., Mocanu, A., Butnariu, L. I., Stoleriu, G., Șalaru, D. L., et al. (2023) · Nutrients · doi:10.3390/nu15112499 · Cited by 36
“These beneficial species, in increased amounts, are reported to lower the production of microbial lipopolysaccharide, leading to an improvement in the host’s immune response [29].”
BackgroundInaba, T., Yamashiro, K., Kurita, N., Ueno, Y., Miyamoto, N., Hira, K., Nakajima, S., Kijima, C., Nakaguro, R., Urabe, T., et al. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14301 · Cited by 32
Cui, Y.-Z., Leng, X.-Y., Zhao, Y.-J., Zhao, Y., & Wang, Q.-J. (2024) · Poultry Science · doi:10.1016/j.psj.2024.103594 · Cited by 32
“At the same time, various members of Bacteroides can reduce the production of lipopolysaccharides by intestinal microorganisms (Yoshida et al., 2018), effectively inhibiting the occurrence of intestinal pro-in fl ammatory response and producing host-absorbable short-chain fatty acids and organic…”
BackgroundGenome plasticity shapes the ecology and evolution of Phocaeicola dorei and Phocaeicola vulgatus
Morais, E. D. S., Grimaud, G. M., Warda, A. K., Stanton, C., & Ross, R. P. (2024) · Scientific Reports · doi:10.1038/s41598-024-59148-7 · Cited by 32
Gastrointestinal surgery and the gut microbiome: a systematic literature review
Ferrie, S., Webster, A., Wu, B., Tan, C. Q. Y., & Carey, S. (2020) · European Journal of Clinical Nutrition · doi:10.1038/s41430-020-0681-9 · Cited by 33
Wang, Y., Jia, Q., Zhang, Y., Wei, J., & Liu, P. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01070 · Cited by 32
“LPS biosynthesis has been proven to up-regulate the atherosclerotic lesion size, plaque area, and the production of IL-4, IL-6, and TNF-a in 16-week-old apolipoprotein E knok out (ApoE) mice (Yoshida et al., 2018).”
BackgroundAverage gut flora in healthy Japanese subjects stratified by age and body mass index
Yoshida, N., Watanabe, S., YAMASAKI, H., SAKUMA, H., Takeda, A., Yamashita, T., & Hirata, K. (2021) · Bioscience of Microbiota Food and Health · doi:10.12938/bmfh.2021-056 · Cited by 31
Self-citationHu, X., Zhou, R., Li, H., Zhao, X., Sun, Y., Fan, Y., & Zhang, S. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.805812 · Cited by 32
“invisus (OTU18) were shown to be greatly enriched in patients with atherosclerotic cardiovascular disease compared with healthy people (45, 46).”
BackgroundThe overlooked benefits of hydrogen-producing bacteria
Ichikawa, Y., Yamamoto, H., Hirano, S., Sato, B., Takefuji, Y., & Satoh, F. (2022) · Medical Gas Research · doi:10.4103/2045-9912.344977 · Cited by 34
Interaction between gut microbiota and immune checkpoint inhibitor-related colitis
Zhou, G., Zhang, N., Meng, K., & Pan, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001623 · Cited by 32
“vulgatus, which has a strong correlation with few irAEs, indicating a potential protective mechanism via LPS reduction (33).”
BackgroundVan den Abbeele, P., Duysburgh, C., Cleenwerck, I., Albers, R., Marzorati, M., & Mercenier, A. (2021) · Microorganisms · doi:10.3390/microorganisms9102142 · Cited by 31
Son, M., Park, I. S., Kim, S., Woo, H. J., Kim, J. H., Kim, T. I., Kim, W. H., Han, J., Kim, S. W., & Cheon, J. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.870817 · Cited by 31
Xu, H., Zhang, X., Li, P., Luo, Y., Fu, J., Gong, L., Lv, Z., & Guo, Y. (2023) · Antioxidants · doi:10.3390/antiox12071476 · Cited by 31
“Bacteroides_dorei reduces lipopolysaccharide production in the intestine and effectively inhibits the proinflammatory response [74]; simultaneously, it can promote the proliferation of Lactobacillus and Bifidobacterium [75].”
Predictive Role of Gut Microbiota in Weight Loss Achievement after Bariatric Surgery
Gutiérrez‐Repiso, C., Garrido‐Sánchez, L., Alcaide‐Torres, J., Cornejo-Pareja, I. M., Ocaña-Wilhelmi, L., García‐Fuentes, E., Moreno‐Indias, I., & Tinahones, F. J. (2022) · Journal of the American College of Surgeons · doi:10.1097/xcs.0000000000000145 · Cited by 33
Yan, H., Vestergaard, G., Deng, L., Kot, W., Thymann, T., Brunse, A., & Nielsen, D. S. (2022) · npj Biofilms and Microbiomes · doi:10.1038/s41522-022-00310-2 · Cited by 31
Impact of the gut microbiome on atherosclerosis
Mao, Y., Kong, C., Zang, T., You, L., Wang, L., Shen, L. W., & Ge, J. (2024) · mLife · doi:10.1002/mlf2.12110 · Cited by 30
“…reduced the level of lipopolysaccharide produced by the gut microbiota, thereby reducing the levels of endotoxin in feces and plasma, enhancing formation of tight junctions in the intestinal epithelium, inhibiting intestinal and systemic in fl ammation, and attenuating atheromatosis 25 .”
BackgroundWei, T., Cao, W., Yu, B., Chen, H., Gong, R., Luorong, Q., Luo, J., Yao, L., & Zhang, D. (2022) · Food & Function · doi:10.1039/d1fo04260b · Cited by 31
Zheng, L., Jiao, Y., Zhong, H., Tan, Y., Yin, Y., Liu, Y., Liu, D. X., Wu, M., Wang, G., Huang, J., et al. (2024) · mSystems · doi:10.1128/msystems.00257-24 · Cited by 31
“B vulgatus and B. dorei can decrease the production of gut microbial lipopolysac charide (102).”
BackgroundAwoyemi, A., Trøseid, M., Arnesen, H., Solheim, S., & Seljeflot, I. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.05.004 · Cited by 30
Li, Y., Ibrahim, R. M. S., Chi, H., Xiao, T., Xia, W., Li, H., & Kang, Y. (2021) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202000885 · Cited by 29
Xiao, R., Liao, W., Luo, G., Qin, Z., Han, S., & Lin, Y. C. (2021) · ACS Omega · doi:10.1021/acsomega.1c03485 · Cited by 28
Role of Biological Sex in the Cardiovascular-Gut Microbiome Axis
Li, S., & Kararigas, G. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.759735 · Cited by 29
Chen, H., Tang, N., Ye, Q., Yu, X., Yang, R., Cheng, H., Zhang, G., & Zhou, X. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1012028 · Cited by 28
“vulgatus has been reported to possibly participate in preventing the pathogenesis of atherosclerosis by reducing lipopolysaccharide production in the gut (Yoshida et al., 2018).”
BackgroundGut Microbiota and Coronary Artery Disease: Current Therapeutic Perspectives
Katsimichas, T., Theofilis, P., Tsioufis, K. P., & Tousoulis, D. (2023) · Metabolites · doi:10.3390/metabo13020256 · Cited by 34
“[46] 2018 Female Wistar rats on a HFD Bacteroides vulgatus Bacteroides dorei Prevention of atherosclerotic plaque formation”
Luo, Z., Yang, L., Zhu, T., Fan, F., Wang, X., Liu, Y., Zhan, H., Luo, D., & Guo, J. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156122 · Cited by 28
Arakawa, K., Ishigami, T., Nakai-Sugiyama, M., Chen, L., Doi, H., Kino, T., Minegishi, S., Saigoh-Teranaka, S., Nakashima-Sasaki, R., Hibi, K., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218096 · Cited by 28
Khan, I., Li, X., Law, B. Y. K., Ka In, U., Pan, B., Lei, C., & Hsiao, W. L. W. (2020) · Future Microbiology · doi:10.2217/fmb-2019-0301 · Cited by 27
Liu, L., He, Y., Wang, K., Miao, J., & Zheng, Z. (2020) · Food & Function · doi:10.1039/d0fo02112a · Cited by 27
New Insights into Stroke Prevention and Treatment: Gut Microbiome
Zhao, L., Yang, L., Guo, Y., Xiao, J., Zhang, J., & Xu, S. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01047-w · Cited by 29
Two Gut Microbiota-Derived Toxins Are Closely Associated with Cardiovascular Diseases: A Review
Yamashita, T., Yoshida, N., Emoto, T., Saito, Y., & Hirata, K. (2021) · Toxins · doi:10.3390/toxins13050297 · Cited by 26
“dorei, in patients with coronary artery disease [4,7].”
BackgroundSelf-citationHu, C., Wang, P., Yang, Y., Li, J., Jiao, X.-L., Yu, H., Wei, Y.-X., Li, J., & Qin, Y.-W. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.560201 · Cited by 26
Chen, Y., Zhang, F., Ye, X., Hu, J., Yang, X. Y., Yao, L., Zhao, B.-C., Deng, F., & Liu, K. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.857035 · Cited by 28
Wang, W., Xu, C., Liu, Z., Gu, L., Ma, J., Hou, J., & Jiang, Z. (2022) · Food & Function · doi:10.1039/d2fo01646j · Cited by 27
Shinohara, R., Nakashima, H., Emoto, T., Yamashita, T., Saito, Y., Yoshida, N., Inoue, T., Yamanaka, K., Okada, K., & Hirata, K. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19422 · Cited by 27
Self-citationLi, N., Wang, L., Li, L., Yang, M.-Z., Wang, Q., Bai, X., Gao, F., Yuan, Y., Yu, Z., & Ren, Z. (2023) · Military Medical Research · doi:10.1186/s40779-023-00489-1 · Cited by 32
“On the other side, transplantation with Bacteroides dorei and Bacteroides vulga-tus or supplementation with Lactobacillus plantarum ATCC 14917 inhibited the formation of atherosclerotic lesions by downregulating serum oxidized low-density lipoprotein, IL-1β and TNF-α in the aorta [117, 118].”
BackgroundExploring the Gut Microbiota–Retina Axis: Implications for Health and Disease
Schiavone, N., Isoldi, G., Calcagno, S., Rovida, E., Antiga, E., Almeida, C. V. D., & Lulli, M. (2025) · Microorganisms · doi:10.3390/microorganisms13051101 · Cited by 27
“Mendelian randomization analyses corroborated these findings, identifying two microbial taxa as risk factors and five as protective, including anti-inflammatory Bacteroides and Burkholderia [124,125].”
Intestinal Flora: A Potential New Regulator of Cardiovascular Disease
Zou, Y., Song, X., Liu, N., Sun, W., & Liu, B. (2022) · Aging and Disease · doi:10.14336/ad.2021.1022 · Cited by 27
“In a study on apolipoprotein E knockout (ApoE−/−) mice [55], it was found that the plasma levels of LPS in mice treated with Bacteroides were significantly reduced, and the plasma levels of atherogenic cell inflammatory factors, such as IL-2 and 4, were lower than untreated control group.”
BackgroundInfluentialIntermittent fasting protects against food allergy in a murine model via regulating gut microbiota
Ma, R.-X., Hu, J., Fu, W., Zhong, J. Q., Cao, C., Wang, C., Qi, S.-Q., Zhang, X., Liu, G., & Gao, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1167562 · Cited by 27
“Bacteroides vulgatus and Bacteroides dorei have been proven to increase ZO-1 expression and improve epithelial barrier function (86).”
BackgroundYang, J., Li, D., Sun, S., Liu, D., Wang, Y., Liu, X., Zhou, B., Nie, W., Li, L., Wang, Y., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111867 · Cited by 25
Curcumin and Gut Microbiota: A Narrative Overview with Focus on Glycemic Control
Servida, S., Piontini, A., Gori, F., Tomaino, L., Moroncini, G., Colonna, V. D. G., Vecchia, C. L., & Vigna, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147710 · Cited by 27
“Some in vivo studies investigated how many and which strains regulate the expression of genes involved in the integrity of the intestinal membrane [41,45,51,52].”
BackgroundCompositional Alteration of Gut Microbiota in Psoriasis Treated with IL-23 and IL-17 Inhibitors
Huang, Y., Chang, L., Chang, Y., Chung, W., Yang, S., & Su, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054568 · Cited by 25
“Moreover, suppression of the systemic and intestinal immune response was observed in mice gavaged with Bacteroides vulgatus [37,38].”
BackgroundJing, J., Guo, J., Dai, R., Zhu, C., & Zhang, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1252907 · Cited by 28
“Bacteroides vulgatus and Bacteroides dorei significantly improve endotoxemia and suppress proinflammatory immune responses by reducing LPS production, thereby delaying the formation of AS (Yoshida et al., 2018).”
BackgroundColaci, C., Gambardella, M. L., Scarlata, G. G. M., Boccuto, L., Colica, C., Luzza, F., Scarpellini, E., Méndez‐Sánchez, N., & Abenavoli, L. (2024) · Hepatoma Research · doi:10.20517/2394-5079.2023.134 · Cited by 27
Gut microbiota in coronary artery disease: a friend or foe?
Zhang, B., Wang, X., Ran, X., & Li, C. (2020) · Bioscience Reports · doi:10.1042/bsr20200454 · Cited by 25
Huang, M., Liu, Y., Dong, W., Zhao, Q., Duan, R., Cao, X., Wan, Y., Yin, J., & Yi, M. (2021) · Chemosphere · doi:10.1016/j.chemosphere.2021.133304 · Cited by 24
Zheng, J., Zhang, L., Gao, Y., Wu, H., & Zhang, J. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.941969 · Cited by 24
Microbiota: A potential orchestrator of antidiabetic therapy
Liu, B., Zhang, L., Yang, H., Zheng, H., & Liao, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.973624 · Cited by 26
“dorei) with potential benefits for T2D have been found to decrease gut microbial LPS production, and effectively suppress pro-inflammatory immune response in a mouse model (103).”
BackgroundDu, Y., & Sun, F. (2023) · Nature Communications · doi:10.1038/s41467-023-41209-6 · Cited by 24
“…gutsamplesbelongedtoonespecies Bacteroidesvulgatus ,whichisone of the most important species in gut environments and plays important roles in inhibiting atherosclerosis and decreasing the production of the gut microbial lipopolysaccharide 37 .”
Nie, H., Zhou, Y., Yu, X., Yin, C., Li, L., Hao, H.-Q., Tao, Y., & Pan, Y. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01238-3 · Cited by 23
“One translational study identi fi ed fecal LPS levels in patients with cardiovascular disease signi fi cantly higher [29].”
Arenas‐Montes, J., Alcala-Diaz, J. F., García-Fernández, H., Gutierrez-Mariscal, F. M., Lopez-Moreno, A., Luque-Córdoba, D., Larriva, A. P. A.-D., Torres-Peña, J. D., Luque, R. M., Prodam, F., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf181 · Cited by 23
Tume, R., Sherbiny, S. E., Bono, R., Gautier, T., de Barros, J.-P. P., & Meroño, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1588129 · Cited by 26
Implications of gut microbiome on coronary artery disease
Xu, J., & Yang, Y. (2020) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-428 · Cited by 22
“Bacteroides dorei in patients with CAD (33)”
BackgroundMethodResultInfluentialYue, S., Wang, W.-X., Zhang, L., Liu, J., Feng, W., Gao, H., Tang, Y.-P., & Yan, D. (2021) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-021-3303-z · Cited by 22
Cheng, H. T., Yen, G., Huang, S., Chen, S., & Hsu, C. (2022) · Journal of Food and Drug Analysis · doi:10.38212/2224-6614.3396 · Cited by 24
Role of Gut Microbiota in Pulmonary Arterial Hypertension
Wu, P., Zhu, T., Tan, Z. Y. A., Chen, S., & Fang, Z. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.812303 · Cited by 23
“, 2017), and gut dysbiosis is associated with a variety of inflammation-related diseases, including atherosclerosis (Jonsson and Bäckhed, 2017; Yoshida et al., 2018; Wu et al., 2021), obesity (Yoshimoto et al.”
BackgroundWiefels, M. D., Furar, E., Eshraghi, R. S., Mittal, J., Memis, I., Moosa, M., Mittal, R., & Eshraghi, A. A. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666221003085508 · Cited by 25
“Bacteroides vulgatus and Bacteroides dorei have similarly yielded increased expression of ZO-1 and improved functioning of the epithelial barrier [103, 105].”
BackgroundLin, H., Chen, J., Ma, S., An, R., Li, X., & Tan, H. (2022) · Nutrients · doi:10.3390/nu14214582 · Cited by 22
“vulgatus can inhibit inflammatory processes and enhance the intestinal barrier [43].”
BackgroundThe Microbial and Metabolic Signatures of Patients with Stable Coronary Artery Disease
Zhong, J., Wu, D., Zeng, Y., Wu, G., Zheng, N., Huang, W., Li, Y., Tao, X., Zhu, W., Sheng, L., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02467-22 · Cited by 24
“CAD patients have been reported to have higher fecal LPS levels than controls (21), and the bowel wall edema and impaired barrier function was often found in heart fail-”
Background
Metadata
- Authors
- Yoshida, N., Emoto, T., Yamashita, T., Watanabe, H., Hayashi, T., Tabata, T., Hoshi, N., Hatano, N., Ozawa, G., Sasaki, N., Mizoguchi, T., Amin, H. Z., Hirota, Y., Ogawa, W., Yamada, T., & Hirata, K.-I.
- Affiliations
- Kobe University (JP)
- Tokyo Institute of Technology (JP)
- Technosuruga Laboratory Co., Ltd. (Japan) (JP)
- University of Indonesia (ID)
- Corresponding author
- Yoshida, Naofumi
- Emoto, Takuo
- ORCID
- Venue
- Circulation
- Published
- 2018-11-27
- Volume
- 138
- Issue
- 22
- Pages
- 2486-2498
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2886282415
- Cited by
- 619
- References
- 50
- Citations by year
- 2026: 52 · 2025: 105 · 2024: 112 · 2023: 113 · 2022: 101 · 2021: 75 · 2020: 47 · 2019: 13 · 2018: 1
- FWCI
- 12.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Kobe University Repository Kernel (Kobe University) (submittedVersion)
- Funders
- Japan Society for the Promotion of Science (16H06279)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- Bacteroides vulgatus, Bacteroides dorei, gut microbiota, atherosclerosis, coronary artery disease, lipopolysaccharide, endotoxemia, pro-inflammatory response, fecal microbiota transplantation, gut-heart axis
- MeSH terms
- Gastrointestinal Microbiome, Aged, Animals, Bacteroides, Feces, Female, Humans, Intestines, Lipopolysaccharides, Male, Mice, Inbred C57BL, Middle Aged, Risk Factors, RNA, Ribosomal, 16S, Sequence Analysis, RNA, Mice, Knockout, Immunity, Mucosal, Tight Junctions, Atherosclerosis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
